ALT-801 clinical trials
Also written ALT-801.
- studies test it
- 11
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How each study uses ALT-801 is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
11 studies that test it; most in 2022 (3)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2020 | 1 |
| 2021 | 1 |
| 2022 | 3 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 0
Altor BioScience (6) · Altimmune, Inc. (5)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ALT-801 is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 11
- QUILT-2.008: Study of ALT-801 With Cisplatin in Patients With Metastatic MelanomaTerminatedPhase 1/2Altor BioScienceNCT01029873Written as ALT-801How we know
- ALT-801 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus (T2DM)CompletedPhase 1Altimmune, Inc.NCT05134662Written as ALT-801How we know
- ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and TolerabilityCompletedPhase 1Altimmune, Inc.NCT04561245Written as ALT-801How we know
- A Study of ALT-801 in Patients With Bacillus Calmette-Guerin (BCG) Failure Non-Muscle Invasive Bladder CancerTerminatedPhase 1/2Altor BioScienceNCT01625260Written as ALT-801How we know
- A Study of ALT-801 in Combination With Cisplatin and Gemcitabine in Muscle Invasive or Metastatic Urothelial CancerCompletedPhase 1/2Altor BioScienceNCT01326871Written as ALT-801How we know
- QUILT-3.020: A Study of ALT-801 in Patients With Relapsed or Refractory Multiple MyelomaTerminatedPhase 1/2Altor BioScienceNCT01670994Written as ALT-801How we know
- Efficacy and Safety of ALT-801 in the Treatment of ObesityCompletedPhase 2Altimmune, Inc.NCT05295875Written as ALT-801How we know
- ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With Non-alcoholic Fatty Liver Disease (NAFLD)CompletedPhase 1Altimmune, Inc.NCT05006885Written as ALT-801How we know
- Extension of ALT-801 in Diabetic and Non-Diabetic Overweight and Obese Subjects With (NAFLD)CompletedPhase 1Altimmune, Inc.NCT05292911Written as ALT-801How we know
- ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid LeukemiaWithdrawnPhase 1Altor BioScienceNCT01478074Written as ALT-801How we know
- Safety and Efficacy Study of ALT-801 to Treat Progressive Metastatic MalignanciesCompletedPhase 1Altor BioScienceNCT00496860Written as ALT-801How we know
Codes
What other systems call ALT-801 · ClinicalTrials.gg INT006071
- MeSH (NLM) C572627ALT-801One source ClinicalTrials.gov
- UNII (FDA) QWZ40O5W6KALT-801One source FDA
- NCI Thesaurus C71743IL-2 Recombinant Fusion Protein ALT-801One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C572627 | ALT-801 | One source ClinicalTrials.gov |
| UNII (FDA) | QWZ40O5W6K | ALT-801 | One source FDA |
| NCI Thesaurus | C71743 | IL-2 Recombinant Fusion Protein ALT-801 | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.